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Abstract
The protozoan parasite Trypanosoma cruzi is the etiologic agent of Chagas disease, a neglected tropical infection that
affects millions of people in the Americas. Current chemotherapy relies on only two drugs that have limited efficacy and
considerable side effects. Therefore, the development of new and more effective drugs is of paramount importance.
Although some host cellular factors that play a role in T. cruzi infection have been uncovered, the molecular requirements
for intracellular parasite growth and persistence are still not well understood. To further study these host-parasite
interactions and identify human host factors required for T. cruzi infection, we performed a genome-wide RNAi screen using
cellular microarrays of a printed siRNA library that spanned the whole human genome. The screening was reproduced 6
times and a customized algorithm was used to select as hits those genes whose silencing visually impaired parasite
infection. The 162 strongest hits were subjected to a secondary screening and subsequently validated in two different cell
lines. Among the fourteen hits confirmed, we recognized some cellular membrane proteins that might function as cell
receptors for parasite entry and others that may be related to calcium release triggered by parasites during cell invasion. In
addition, two of the hits are related to the TGF-beta signaling pathway, whose inhibition is already known to diminish levels
of T. cruzi infection. This study represents a significant step toward unveiling the key molecular requirements for host cell
invasion and revealing new potential targets for antiparasitic therapy.
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Introduction
Chagas disease, also known as American trypanosomiasis, is a
neglected disease that affects millions of people in the Americas.
The Drugs for Neglected Diseases initiative [DNDi] (http://www.
dndi.org/diseases/chagas/global-view.html) estimates that more
than 8 million people are infected and 100 million people are at
risk of infection [1]. Chagas disease accounts for 667,000
disability-adjusted life years (DALYs) in Latin America and kills
more people than any other parasite-borne disease, making it the
most important parasitic disease on the continent [2].
Previously confined to endemic countries in Latin America,
increasing numbers of patients are being reported in non-endemic
developed countries such as the United States, Spain, Australia
and Japan due to an increased influx of people from endemic
countries unknowingly carrying the parasite [3].
Despite being significantly debilitating and causing great social
and economic disruption, Chagas disease is still considered a disease
of poverty. Current chemotherapy has proven effective for the acute
phase of the disease that is recognized only in an estimated 1–2% of
all individuals acquiring the infection [4]. Therefore, there is no
efficient drug for the vast majority of patients who are in the chronic
phase of the disease. The currenttreatmentoptions,Nifurtimox and
Benznidazole, show low efficacy and numerous side effects (http://
www.dndi.org/diseases/chagas/current-treatment.html) [5]. Al-
though new drugs could potentially solve the problem, Chagas
disease is one of the most neglected diseases in terms of drug
development [6].
Trypanosoma cruzi is the etiologic agent of Chagas disease, and it
progresses through four developmental stages during its life cycle,
alternating between insect vectors and mammalian hosts [7]. This
protozoan parasite is able to invade and multiply inside a broad
range of mammalian cells. Different routes of invasion mediated
by distinct cell surface receptors, secondary messengers, and
transcription factors have been described [8,9]. Once inside the
host cells, T. cruzi trypomastigotes disrupt the parasitophorous
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amastigotes. These forms multiply by binary fission, differentiating
back into trypomastigotes before bursting out of the host cell to
invade surrounding cells or reach the bloodstream to infect remote
tissues [7].
T. cruzi isolates present extensive biological, biochemical and
genetic diversity [10–12]. The clinical manifestations of the disease
can vary from a symptomless infection to a severe chronic disease
with cardiovascular or gastrointestinal involvement. Genetic
variation of both the host and the parasite likely plays key roles
in the outcome of the disease, suggesting genetic individuality of
parasite clones [13,14]. At least 6 different subgroups of T. cruzi
have recently been recognized based on genetic, molecular or
immunological markers [12]. Equally elaborated is the multi-step
process used by these parasites to enter and multiply into their host
cells, involving various parasitic and cellular molecules and
ultimately leading to intracellular calcium mobilization in both
cells and parasites [9,15,16]. Taken together, these studies
highlight the complexity of this parasite and of its interaction
with the host and thus explain why the molecular requirements for
parasite intracellular growth and persistence are not yet fully
understood.
The use of reverse genetic tools such as RNA interference
(RNAi) therefore represents an alternative strategy to identify
host proteins that might be important for T. cruzi invasion,
intracellular parasite survival and proliferation. Recently, it has
been shown that silencing laminin c-1 expression in cultured
human coronary artery smooth muscle cells rendered them
significantly more resistant to parasite attachment and intracel-
lular proliferation [17]. Using a similar approach, the same
authors demonstrated that stable interference of thrombospon-
din-1 expression in cultured HeLa cells in vitro resulted in an
increased resistance to T. cruzi invasion [18]. Moreover, silencing
cytokeratin 18 inhibited intracellular proliferation of Y and CL
strains of T. cruzi in HeLa cells [19]. Other experiments,
including transcriptome profiling and host gene-expression
analyses of T. cruzi-infected cells [20–22], have uncovered many
possible key players in this interaction; however, only some of the
host metabolic and signaling pathways were found to be shared
by different cell types [20].
Recently, several genome-wide RNAi screens have been used to
elucidate the mechanisms involved in host-pathogen interactions
[23–25], all of them using microplate-based assays. In addition,
several research groups have recently published studies identifying
the host proteins required for HIV infection using similar
microplate-based approaches [26–28], although surprisingly very
little overlap was found among the identified proteins. This
discrepancy could be explained, according to the authors, by small
technical differences between the experiments [28] that may have
been further evidenced by the variations between microplate wells.
In order to achieve a more homogeneous screening, we used a new
approach relying on the use of glass microarrays that permitted us
to increase the throughput and eliminate well-to-well variations,
generating an unbiased and more uniform analysis.
A prototype of a cellular microarray-based RNAi screening over
glass slides method was first described by Erfle and collaborators in
2004 [29] and was further developed for high-throughput scale in
genome-wide screens investigating mitosis, cell cycle progression
and constitutive protein secretion machinery [30–32]. This type of
reverse transfection approach shows several advantages over
microplate-based screens: i) reduced costs due to the small amount
of small interfering RNA [siRNA] and other reagents needed, ii)
faster data acquisition due to the high number of experiments per
array, and iii) low heterogeneity due to the absence of physical
barriers between experiments, thus increasing screening data
quality [30].
In this study, we used a cellular microarray-based RNAi
screening as a primary step to search for human cell factors that
play a role during infection by the protozoan parasite T. cruzi. The
strongest primary screening hits were subsequently submitted to a
secondary screening and later confirmed using individual siRNAs
in two different cell lines. Overall, our screening strategy allowed
us to identify and validate 14 genes whose silencing impaired T.
cruzi infection, providing clues about the molecular mechanisms
that guide the infection process.
Methods
Chemicals
All chemicals were purchased from Sigma-Aldrich. DRAQ5
was purchased from BioStatus (Shepshed, UK). All siRNA
duplexes were purchased from Dharmacon (USA). The siRNA
library comprised 0.5 nM of the Dharmacon siARRAY whole
human genome siRNA library (Thermofisher, West Lafayette,
CO) containing 84,508 siRNAs corresponding to four unique
siRNA duplexes, targeting 21,127 unique human genes. Primary
antibody against p65 was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA) and the fluorescent secondary antibody
Alexa Fluor 488 was purchased from Molecular Probes, Invitrogen
(Carlsbad, CA). Transfection reagents were purchased from
Qiagen (Valencia, CA). All culture media and their supplements
were purchased from Gibco (Invitrogen, Carlsbad, CA).
Microarray Printing
siRNA transfection solution was prepared as described previ-
ously [29,30,32–34] and printed as 3888 spot arrays (108636
spots) on No. 1 glass coverslips (Marienfeld, Germany) using
stealth pins (Telechem, USA) and a high-throughput microarray
printer (Genomic Solutions, USA) at 22–25uC, 55–65% RH
enclosed in a custom built clean chamber providing a sterile
HEPA filtered atmosphere. To facilitate spot localization, siGLO
Red dye (Dharmacon, Thermofisher) was also incorporated
into the transfection solution. Printed arrays were stored in a
desiccating chamber and showed no significant alterations in
performance from one week up to 21 months post-printing. Seven
printed slides covered a single human genome in siRNA and
contained 2% of control siRNA spots (scrambled siRNA).
Cell and Parasite Cultures
U2OS, HeLa and LLC-MK2 cells (ATCC, Manassas, VA)
were cultured in DMEM high-glucose medium supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a
humid atmosphere of 5% CO2 at 37uC.
U2OS are osteosarcoma cells that can be easily transfected with
siRNAs and infected by T. cruzi parasites, being successfully adapted
to our microarray model. They present a large cytoplasm that
facilitates parasite detection and grow preferentially in monolayers,
which is crucial for individual cell quantification during software
analysis. Little overlap has been observed among different infected
hostcellsin mRNAprofilingstudies [20], soto check if ourhits were
cell-specific, we also tested the individual siRNAs in HeLa cells, a
cell line more commonly used for T. cruzi infection.studies.
LLC-MK2 (monkey kidney epithelial cells) were used to
maintain in vitro culture of trypomastigotes. Tissue culture-derived
trypomastigotes (TCTs) of Trypanosoma cruzi strain Dm28c [35]
were harvested from the supernatants of infected LLC-MK2
cultures maintained in DMEM Low Glucose medium (Gibco)
containing 2% FBS and 1% penicillin/streptomycin. T. cruzi
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(DTU TcI) based on the most recent nomenclature [12].
Validation of the Microarray Screening and p65
Immunofluorescent Detection
To validate the transfection efficiency of the microarray screen,
2610
6 U2OS cells were seeded onto reverse transfection arrays
comprising 250–300 mm spots spaced at 500 mm intervals on a
glass wafer (class 1, 130–160 mm thickness). Spots contained either
p65 specific or control siRNAs in addition to a red fluorescent
oligonucleotide (siGLO Red) in an encapsulation mixture and
were printed using SMP9 pins in a stealth printhead mounted in a
Gene Machines Omnigrid HT array spotter. Cells were incubated
for 48 hours at 37uC to allow for silencing.
For the immunofluorescent detection of p65, cells were washed
twice with phosphate-buffered saline (PBS), fixed for 10 minutes
with 4% (w/v) paraformaldehyde in PBS, and then washed once
with PBS. Permeabilization was performed using 0.1% Triton X-
100 in PBS for 15 min, followed by washing in PBS. All the
procedures above were performed at room temperature. Cells
were then incubated with a 1:200 dilution of rabbit anti–p65
antibody in 10% goat serum overnight at 4uC. On the following
day, cells were washed 3 times with PBS for 10 minutes on an
orbital rotator and incubated with Alexa Fluor 488 goat anti-
rabbit secondary antibody (1:800) for 60 minutes at room
temperature. Cells were washed 3 times for 10 minutes each with
PBS on an orbital shaker prior to the addition of 5 mM of DRAQ5
in PBS and incubation for 10 minutes at room temperature.
Confocal images were acquired using an ImageXpress Ultra point
scanning confocal microscope (Molecular Devices, USA). Quan-
tification of p65 silencing was performed using MetaXpress
software (Molecular Devices), dividing the average p65 intensity
by total cell number of each acquired image.
Primary Screening and Microarray Infection
For the Primary Screening, U2OS cells were plated at a density
of 1610
6 cells/dish onto printed siRNA arrays and cultivated in
Opti-MEM I medium supplemented with 5% FBS and 1%
penicillin/streptomycin in a humid atmosphere of 5% CO2 at
37uC for 48 hours. Cells were infected with 1610
6 TCTs/ml in
25 ml (approximate ratio of 25 parasites per cell) and incubated
for 8 hours at 37uC. After that period, free TCTs were washed out
and cells were cultivated in fresh Opti-MEM I supplemented
medium at 37uC for additional 28 hours. At a total of 36 hours
after the beginning of the infection, arrays were fixed in 4% (w/v)
paraformaldehyde in Dulbecco’s phosphate-buffered saline
(DPBS, Invitrogen) at room temperature and stained with
2.5 mM DRAQ5 before imaging (see Figure S1).
Microarray Acquisition
Images covering the entire surface of the slides were acquired
with a 206objective using an ImageXpress Ultra microscope and
directly saved as 16 bit TIFF files on an external database. Each
scanned slide comprised 1820 confocal pictures in two channels
(siGLO Red and DRAQ5) with a size of 100061000 16-bit pixels
each. Consequently, the size of an acquired array was roughly 7
gigabytes, and hence a genome screen composed of 7 arrays was
roughly 50 gigabytes total. The genome screening was replicated 6
times. Because each array contained 3888 spots, we obtained a
total of 163,296 visual experiments and acquired 76,440 images.
Images were read directly from the database for image
reconstruction and analysis using software designed for this
purpose (described below).
Software Development for Spot Recognition
We developed in-house dedicated software, called IM, which
allowed for the assemblage, miniaturization, grid fitting, image
reconstruction and analysis of each individual spot. Each spotted
experiment could lie either on one or across two to four pictures
because the pictures were acquired regardless of spot location. A
miniature image of the whole slide was produced by reducing the
size of 1820 images by a factor of 3/100. Adaptive grid fitting was
applied to identify siRNA spots on the miniature image of the
array. Each spot had coordinates that reported them to the high
resolution image database that was used to extract pieces of
pictures needed to reconstruct individual annotated spotted
experiments.
Software Development for Image Analysis
Dedicated image analysis was developed and integrated into the
same software to quantify individual cells in each experiment.
Briefly, an algorithm was designed to optically address each spot
where the siRNAs were printed and another was created to
artificially emphasize nuclei and parasites in different colors. The
resulting artificial two-color images were used by the software to
detect and quantify each individual cell and parasites per cell. For
the primary screening, we retrieved cell number and the median
number of parasites per cell over a spot. For secondary and
tertiary screenings, we retrieved the ratio of infected cells (infected
was defined as a cell containing at least one parasite), the median
and the average number of parasites per cell, and the average
number of parasites per infected cell.
Data Analysis during Primary Screening
There were 6 spotted experiments (replicates) per gene in the
primary screening. Cell distribution was normalized in each array
prior to analysis and the number of cells and median number of
parasites per cell were calculated for each visual experiment. We
then selected the replicates that simultaneously presented a cell
number higher than the mean minus two standard deviations and
a median number of parasites lower than the mean minus two
standard deviations when compared to the negative control
distribution (scrambled siRNA). Cell number was considered along
with the number of parasites per cell in order to remove from the
analysis genes that when knocked down were toxic to the cells.
The selection based on these two criteria represented the results of
roughly 3.75% of all experiments. Hits were extracted from this
selection using the method described below.
If a set of 6 experiments were to be selected randomly among all
experiments, then 3.75% would fall into the selected experiments.
Therefore, we compared the ratio of experiments falling in the
selection for 6 experiments (replicate) of each gene to the ratio for
a random sample. Following this concept, a gene was defined as a
hit when the ratio of its selected replicates was at least five times
higher than the ratio of a randomly chosen experiment. For
example, for the gene MGC33951, the exact results were as
follows: 2 of its 6 replicate siRNA spots were accidentally not
printed, two fell into the selected area using the criteria described
above and two fell outside. Therefore, 50% (2 among 4) of the
MGC33951 replicates fell into 3.75% of the total selected
experiments, showing a ratio score of 0.07=0.5/0.0375 that is
lower than 0.2 (0.2 corresponds to a ratio 5 times higher 5=1/
0.02). The score of 0.07 is also much lower than 1, which
corresponds to a random selection. A score of 0.07 represents a
probability 14 times higher for a replicate of that gene to fall in the
selection (equivalent to a p-value of 1.84610E-4) and therefore
cannot be explained just by chance. Using this method, a total of
277 genes were selected.
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Screening
To confirm the hits identified during primary screening, we
performed a secondary screen in 96-well plates. To validate this
format, U2OS cells were transfected with either scrambled or p65
specific siRNA, as suggested by the manufacturer and subse-
quently infected with T. cruzi trypomastigotes and immunostained
for p65 protein. Briefly, U2OS cells were trypsinized one day prior
to transfection, diluted in fresh DMEM high glucose medium
supplemented with 5% FBS without antibiotics and transferred to
96-well plates (Greiner). A total of 5000 U2OS cells were seeded
per well and cultured for 16 hours. Transient transfection of
siRNAs was performed using DharmaFECT 1 (Dharmacon,
Thermofisher). For each well, 9.9 ml of serum-free DMEM and
0.1 ml of DharmaFECT 1 were preincubated for 5 minutes at
room temperature. At the same time, 5 ml of serum-free DMEM
was mixed with 5 ml of each siRNA (1 mM) and incubated for
5 minutes at room temperature. The two mixtures were combined
and incubated for 20 minutes at room temperature to allow for
complex formation. After the addition of 80 ml of complete
DMEM medium to the mixture, the entire solution was added to
the cells in each well, resulting in a final concentration of 50 nM
for the siRNAs. After transfection, cells were incubated for
48 hours to allow gene silencing. Cells were infected with 1610
6
parasites/ml (100 ml/well) for 8 hours before free parasites were
washed out. Cells and intracellular parasites were then incubated
in fresh DMEM supplemented medium for additional 28 hours.
Cells and parasites were fixed and stained with DRAQ5 as
described for the primary screening. In addition, cells were
immunostained for p65 protein under the following conditions: in
the absence of parasites, in the absence of siRNA, in the presence
of scrambled siRNA or in the presence of p65 siRNA. Labeling
intensity was measured using the MetaXpress software (Molecular
Devices).
After visual inspection, 162 hits selected from the primary
screening hit list were assayed again in a secondary screening. All
of the procedures for seeding, transfection, infection and staining
were exactly the same as described for the validation assay. The
secondary screening experiment was performed in duplicate.
To further select the hits from the secondary screening and
assess more precisely how the parasite infection was modified by
the knockdown of genes, four parameters were considered during
the analysis as described above: i) ratio of infected cells, ii) median
parasite number per cell, iii) average number of parasites per cell,
and iv) number of parasites per infected cell. The selected genes
were those ones that scored lower than the mean minus one time
the standard deviation of the negative control distribution
(scrambled siRNA) in at least one of the four parameters
mentioned above, in both duplicates. The genes that came out
only in one of the replicates were discarded. Using this method, a
total of 15 genes were selected.
Confirming Specificity of the siRNAs
To exclude possible off-target effects due to pooled siRNA
duplexes, a third assay using single siRNA duplexes was performed
for 13 of the hits identified in the secondary screen. For these
experiments, all procedures were performed in exactly the same
way described for the secondary screen, except that 4 single siRNA
duplexes were individually tested to silence each gene. The four
parameters assessed to confirm the hits were the same as those
described for the secondary screen (see above). The selected genes
were those that scored lower than the mean minus one time the
standard deviation of the negative control distribution (scrambled
siRNA) in at least one of the four parameters in both duplicates.
All the hit genes tested were confirmed using this method.
The methodology used for this validation was similar to the one
performed with U2OS. The experiment was repeated twice and
three parameters were taken into consideration when selecting
hits: i) ratio of infected cells, ii) average number of parasites per
cell, and iii) number of parasites per infected cell. The hit genes
were those ones that scored lower than the mean minus one time
the standard deviation of the negative control (scrambled siRNA)
in at least one of the parameters mentioned above in both
duplicates. Eleven hits were also confirmed in HeLa cells.
RNA Extraction
Total RNA was extracted from U2OS (up to 10
6) cells using
Trizol reagent (Invitrogen). Target RNA was reverse transcribed
using the MMLV reverse transcriptase enzyme (Promega). In the
first step, 5 mM Oligo(dT)16 was added to 0.5–1 mg of total RNA
and annealed at 70uC for 10 min. Then, 100 U MMLV reverse
transcriptase was added in the presence of 50 mM Tris-HCl,
pH 8.3, 75 mM KCl, 3 mM MgCl2, and 5 mM unlabeled
deoxynucleotides (dNTPs) and incubated at 37uC for 60 min.
For each experiment, RT-minus controls were included to provide
a negative control for subsequent PCR reactions. To minimize
variations in reverse transcriptase efficiency, all samples from a
single experiment were reverse transcribed simultaneously.
Real-Time PCR
Real-time PCR was performed using SYBR Premix Ex Taq II
(TaKaRa Bio Inc.) and a MJ Research PTC-200 Thermo Cycler
(BioRad). Template cDNAs were diluted ten-fold and 1–5 ml were
used for amplification in a 20 ml final volume containing 10 mlo f
SYBR Premix Ex Taq II and 0.4 mM of each primer (Table S1).
The protocol included an initial denaturation step at 95uC for
15 min, followed by 32 cycles of 95uC for 20 sec, 60–65uC for
30 sec, and 72uC for 30 sec. After amplification, a melting curve
was obtained by increasing temperatures from 65uCt o9 5 uC with
fluorescence detection at 0.2uC intervals.
The quantification of target gene expression was performed
using the cycle threshold (Ct) value in a PCR amplification curve
by cluster analysis with variable cluster endpoints. Data were
determined from duplicate assays. For normalization, the cell
number in the specimen was determined from the GAPDH gene
quantification.
Results
Microarray Validation
We proved the concept of our microarray methodology by
validating two different controls. The first control was p65 protein,
a component of the NF-kB complex, primarily chosen because its
knockdown could be easily assessed by immunofluorescence
staining. The other control was scrambled siRNA, a siRNA
sequence that does not target any gene in the human genome and
should not affect the knockdown of p65 protein to any extent when
transfected into cells.
For this validation, cells were transfected with either p65 or
scrambled siRNA; after silencing, the cells were fixed and
immunostained against p65 protein. Images were acquired in
three channels, one showing the p65 immunofluorescence
(Figure 1A), a second highlighting the spots where the siRNAs
were printed (Figure 1B) and a third showing the cell nuclei
(Figure 1C). When we analyzed the overlay image of the
3 channels (Figure 1D), it was clear that knockdown of p65
was successfully achieved and was siRNA-specific because its
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containing spots. The p65 labeling intensity of cells transfected
with the p65 siRNA was significantly reduced (56.4% lower,
p,0.0001, n=8) in comparison to cells transfected with
scrambled siRNA (Figure 1E), further confirming knockdown
under the primary screening assay conditions.
Software Development for Image Analysis
Dedicated image analysis software was developed to interpret
the data obtained during the screenings. The original images of
the primary screen, for example, were acquired in two channels
(Figure 2A): one channel shows a spot stained with siGLO Red
(Figure 2B), and another shows cell and parasite nuclei stained
with DRAQ5 (Figure 2D). An algorithm was designed to optically
address each spot (Figure 2C) and hence facilitate gene
localization. In addition, there was a need to distinguish cell
nuclei from parasite nuclei stained with DRAQ5 because they
were both acquired in the same wavelength channel (Figure 2D). A
second dedicated algorithm employed a sequence of morpholog-
ical operators and region growing to artificially emphasize nuclei
in one color (Figure 2E) and parasites in another color (Figure 2F).
This generated artificial two-color image (Figure 2G) could be
easily used by the software to detect each cell and parasite
individually and therefore quantify cells and parasites per cell
(Figure 2H). A real time movie of spot detection and analysis
during the primary screen can be seen in the Supporting
Information section (Video S1).
Primary Screening Using Microarrays
The genome-wide screening was performed in 6 independent
experiments to obtain a good statistical sampling and to ensure
that no spot would be missed. If each spot is defined as re-
presenting a single experiment, then our data corresponded to a
total of 163,296 experiments.
We found some host genes that, when knocked down, impaired
trypomastigote entrance and/or amastigote proliferation inside
host cells. They accounted for 277 genes that received different
scores based on their performance in terms of percentage of
infected cells, median parasite number per cell, and number of
parasites per cell.
Figure 1. Proof-of-concept of the microarray screening. U2OS cells were seeded onto reverse transfection arrays comprising 250–300 mm
spots spaced center-to-center at 500 mm intervals on a glass wafer. Spots contained p65 specific or control siRNAs (scrambled siRNA) and a red
fluorescent siRNA in an encapsulation mixture (siGLO Red). Cells were incubated for 48 hours and then fixed and stained with anti-p65 antibodies.
Confocal images were acquired 48 hours post-transfection. Scrambled siRNA was chosen as a negative control because it does not target any gene in
the human genome. (A) Anti-p65 labeling of two p65 and two scrambled siRNA spots. (B) Spot images labeled with siGLO Red. (C) DNA staining
(DRAQ5) showing an equal distribution of cells. (D) Overlay image. Scale bar represents 250 mm. (E) Quantification of p65 silencing using MetaXpress
software (Molecular Devices). Plot showing p65 labeling (intensity/pixel/cell) for cells outside spots or overlaid on scrambled siRNA or p65 siRNA
containing spots. ***p,0.0001 (unpaired t-test), n=8.
doi:10.1371/journal.pone.0019733.g001
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The gene coding for protocadherin alpha 13 [PCDHA13]
(Figure 3A) was found among the first 126 hits and had a p-
value of 8.72E-04. The chromosome 20 open reading frame 200
[C20orf200] (Figure 3B) scored among the first 85 hits, showing a
p-value of 4.48E-04. As a negative control for the experiment,
approximately 2% of all the microarray spots contained scrambled
siRNAs (Figure 3C). Moreover, specific siRNAs targeting p65
protein, as used in our proof-of-concept experiment shown in
Figure 1, were also spotted on the microarrays to ensure
transfection efficiency, and they showed no effect over T. cruzi
infection (Figure 3D).
Secondary Screening and Confirmation of siRNAs
Specificity
The 162 genes with the highest scores were retested in a
secondary screening assay in 96-well plates that is a robust and
well-established format regularly used for screenings. As was
performed for the microarray technology, this 96-well format also
had to be validated before proceeding with the screening.
Therefore, U2OS cells were transfected with scrambled siRNA
or p65 siRNA and subsequently immunostained for p65 protein.
The amount of p65 protein present in the cytoplasm of cells
transfected with p65-targeting siRNA (Figure 4A, rightmost
column) was lower than the amount found in scrambled siRNA-
Figure 2. Microarray screening image analysis. Schematic illustration of how the developed software recognized the siRNA spot, the cells and the
parasites forsubsequentmeasurements. (A) All imagesoftheT.cruziprimaryscreeningwere acquiredintwodifferent channels,asshownin(B) and(D).
(B and C) Optically addressable siRNA spots were labeled with siGLO Red to enable their localization on the arrays. (D) Cell and parasite nuclei were
stainedusing DRAQ5.As therawimageswere acquiredin a single wavelength, cells andparasites were artificiallyseparatedandemphasized in different
colors (E and F, respectively), generating artificial two-wavelength images (G). This allowed for individual cell detection and quantification of several
independent descriptors to measure infection (H). An enlarged panel showing cell detection by the software in greater detail is in the bottom left. The
cell nuclei and boundaries are outlined in white and yellow/green, respectively (arbitrary colors). Scale bar represents 150 mm.
doi:10.1371/journal.pone.0019733.g002
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Moreover, this lower amount of cytoplasmic protein was revealed
to be independent of parasite or siRNA presence (Figure 4A, two
leftmost columns). Nuclei staining is shown in Figure 4B and
overlay images in Figure 4C. The overlay images, as well as the
wide view of the experiment plate in the bottom panel, clearly
demonstrate the silencing of the p65 protein (rightmost column) in
comparison to other treatments.
After validating the plate format, a secondary screening was
carried out in duplicates containing the strongest 162 hits selected
previously from the primary screening. Fifteen genes were
confirmed as hits because their silencing reproduced the inhibitory
effect on the T. cruzi infection process. However, one of the hits
(LOC400729) was not considered for further analysis because its
record was discontinued from Entrez Gene public database. The
remaining 14 human genes that proved to be important for T. cruzi
infection are listed on Table 1.
In addition, we performed two new assays as a means to confirm
the specificity of the siRNAs and exclude possible off-target effects
caused by the siRNA pools used during the primary and secondary
screenings. For the first assay, the four individual siRNA duplexes
that composed the pool for each gene were separated and indi-
vidually transfected into U2OS cells in 96-well plates following the
same experimental conditions used for secondary screening.
Because individual siRNA duplexes targeting the olfactory re-
ceptor family 2 subfamily T member 5 [LOC401993] were not
available for purchase at the time these experiments were
conducted, this validation assay was performed with the remaining
13 genes (see Table 1). All genes tested were confirmed as hits by
at least two of the siRNA duplexes (data not shown), suggesting
that the siRNA pools used previously were specific to their
corresponding genes and that the inhibitory effect that occurred
upon infection was not due to off-target effects. The four
individual siRNA duplexes silencing calcium binding protein 2
[CABP2], for example, target different regions of the gene and do
not overlap each other (Figure 5A). In this case, even when
transfected individually, each of the four siRNA duplexes was able
to silence the CABP2 gene in host cells, resulting in a reduced
infection by T. cruzi parasites in comparison to scrambled siRNA-
transfected cells (Figure 5B).
In a second validation assay, we decided to check if these hits
were cell-specific, since a previous study showed that little overlap
Figure 3. Genome-wide microarray screening results. Examples
of data from the primary screening performed over microarrays
showing that the knockdown of some genes inhibited infection by T.
cruzi parasites. In (A) and (B), two examples are shown of genes
selected as hits: PCDHA13 (protocadherin alpha 13) and C20orf200
(chromosome 20 open reading frame 200), respectively. Scrambled
siRNA (C) was used as a negative control and p65 siRNA (D) was used as
a transfection control (see Materials and Methods). Cells and parasites
are pseudocolored in white, while siRNA spots are pseudocolored in
red. The yellow dashed boxes outline the spot region. Cells within the
spot were silenced for the indicated genes and compared with the cells
lying outside the spot for their infection ratio and parasite load through
software analysis. Scale bar represents 80 mm.
doi:10.1371/journal.pone.0019733.g003
Figure 4. Validation of the secondary screening. The secondary
screening was performed in 96-well plates. To validate this format,
U2OS cells were seeded, transfected with the appropriate siRNAs and
then infected with T. cruzi trypomastigotes as detailed in Materials and
Methods. From left to right, cells were immunostained for p65 protein
in the absence of T. cruzi parasites, in the absence of siRNAs, in the
presence of scrambled siRNA or in the presence of p65 siRNA,
respectively. (A) Immunofluorescence staining against p65 protein
(green). (B) DNA staining of cell and parasite nuclei (DRAQ5, purple).
(C) Overlay images. In the bottom panel, a wide view of the plate wells,
showing p65 protein labeling (green) and cells (white). The rightmost
column evidences the p65 knockdown when cells were transfected
with p65 siRNA. Scale bar represents 80 mm.
doi:10.1371/journal.pone.0019733.g004
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19733is found in the signaling pathways affected by T. cruzi infection in
different cell lines [20]. With this aim, we performed the same
experiment with individual siRNAs using HeLa cells instead of
U2OS cells, because HeLa is commonly used as the host cell in T.
cruzi invasion assays [9]. Most of the genes validated with
individual siRNAs in U2OS cells also interfered with infection of
HeLa cells, except LOC389895 (Hypothetical LOC389895) and
MGC33951 (Chromosome 15 open reading frame 43) that were
found to be specific for the osteosarcoma cell line (data not shown).
To evaluate the messenger RNA [mRNA] transcript levels of
the genes after transfection with the siRNAs, we selected four hits
and performed quantitative real-time polymerase chain reaction
[qRT-PCR] assays using the SYBR Green method. The
quantification of the target genes was performed using the cycle
threshold [Ct] value in a PCR amplification curve. The results
showed that the transcripts of the 4 genes were down regulated
when compared to scrambled siRNA-transfected samples, knock-
ing down approximately 80% of cadherin 11 type 2 OB-cadherin
[CDH11], 40% of calcium binding protein P22 [CHP], 70% of
fucosyltransferase 8 [FUT8], and more than 95% of chromosome
1 open reading frame 43 [NICE-3] mRNA transcripts (Figure 6).
Discussion
T. cruzi is able to invade almost any nucleated mammalian cell
type and facilitates its own entry by actively manipulating the host
cell [8,9]. This complex interaction between T. cruzi and its host
cells during the process of infection is primarily mediated by
interplay of signaling cascades that involve both parasitic and
cellular factors [36]. Some of the parasites’ primary tools for
entering host cells during the infection process are their surface
glycoproteins, in particular mucins and trans-sialidases, and their
specific proteinase cruzipain [37]. Although several important
parasite factors have been discovered, little is known about the
roles of host cell proteins in this process. The limited information
available reveals that some cell receptors, including cytokeratin 18,
galectin-3 and P74, may be involved in parasite adhesion to
mammalian cells [19,38,39]. Recent evidence also indicates that
T. cruzi is able to modulate the extracellular matrix network to
promote its invasion of human cells, increasing levels of laminin c-
1 and thrombospondin-1, and binding to fibronectin [17,18,40].
RNA interference (RNAi) has increasingly been used to uncover
the roles of specific host cell proteins, demonstrating the effects of
individual gene silencing on T. cruzi infection [17–19]. However,
these experiments were usually focused on genes belonging to
pathways previously identified as important for the T. cruzi
infection process. To broaden the view of the host genes that are
affected by T. cruzi infection, Costales and colleagues have recently
studied the transcriptional response triggered by T. cruzi infection
in phenotypically diverse human cell types [20]. They found that
only a small fraction of host metabolic and signaling pathways
were shared by the different cell types tested, suggesting that
intrinsic host cell metabolic differences might be determining
factors for the response to infection. Imai and colleagues [21] also
performed a microarray analysis of host gene expression during
the intracellular nest formation of T. cruzi amastigotes. However,
his results showed little or no overlap with Costales’ results,
indicating that each single condition used during the experiment,
i.e., cell type, parasite strain or time of infection, could have
dramatic effects on the output of the assay.
The aim of this work was to better understand the interactions
between T. cruzi and its host cells by searching for cell factors that
could affect the T. cruzi infective process. Our first step was to
develop a genome-wide RNAi screen to be as unbiased and
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19733homogeneous as possible, eliminating the physical separations
present in microplate-based assays and taking advantage of the
great number of experiments performed simultaneously in a single
array. This primary screening using the microarray methodology
served as a first filter to provide us with a smaller number of hits,
and it can be used successfully in the future to understand other
mechanisms and host-parasite interactions in different organisms.
In a secondary screening, we confirmed the inhibitory effects of
15 genes on the infection ratio among 162 genes that showed a
strong inhibitory effect. The fact that only about 10% of the hits
were confirmed in the secondary screening must be a consequence
of subtle differences that can affect T. cruzi infection. In the
primary screening, the intricate combination of a sensitive
microarray format with this complex parasite, and the lack of a
positive control as a direct phenotype during analysis, led us to use
simple parameters to extract the hits and therefore increase the
number of artifacts. By contrast, the microplate format used for
the secondary screening likely offered higher assay stringency in
comparison with the microarray format and consequently
restricted the number of hits obtained. This higher stringency
could be explained by factors such as more homogeneous
distribution of cells and different transfection conditions. Never-
Figure 5. Confirming specificity of siRNA silencing. To confirm
specificity and exclude off-target effects of the siRNA pools used in the
primary and secondary screens, the 4 different siRNA duplexes from the
pool targeting each gene were separated and individually transfected
to U2OS cells in 96-well plates following the same experimental
conditions used for secondary screen. (A) Schematic representation of
the four siRNAs targeting the calcium binding protein 2 (CABP2) mRNA
sequence. bp=base pairs. (B) Pictures showing CABP2 gene silencing
using the four different siRNAs depicted in (A). U2OS cells were
transfected with each one of the siRNAs and then infected with T. cruzi
parasites. Pictures a, b, c and d show a decrease in infection when
compared to scrambled siRNA (bottom picture). All 13 genes tested
were confirmed by at least two individual siRNAs, demonstrating that
the infection inhibition seen in primary and secondary screens was not
due to an off target effect. Scale bar represents 80 mm.
doi:10.1371/journal.pone.0019733.g005
Figure 6. Checking mRNA levels by quantitative real-time PCR.
U2OS cells were transfected with the siRNAs (scrambled siRNA, CDH11,
CHP, FUT8 and NICE-3) and total RNA was isolated from each sample
after a 48-hour incubation. cDNAs were prepared and endogenous
mRNA levels were measured using real-time PCR. The relative copy
numbers of the transcripts were normalized to GAPDH and the
knockdown was quantified using scrambled siRNA as the negative
control.
doi:10.1371/journal.pone.0019733.g006
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PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19733theless, for our purposes, the priority was to confirm that the hits
were real and robust, and therefore we decided to further explore
these results.
Screenings that use siRNA pools have several significant
advantages over identical screens using corresponding individual
siRNA duplexes, especially for high-throughput purposes. How-
ever, despite generating more evident phenotypes than any of the
corresponding single siRNA duplexes, these pools might result in
some false positive hits [41]. To evaluate the veracity of the hits
from the secondary screening, we tested the knockdown of 13
genes using 4 separated siRNAs per gene, and we confirmed that
all of them showed inhibitory effects over T. cruzi infection with at
least 2 of the 4 single siRNAs. The fact that even individual siRNA
sequences were able to silence each gene, consequently decreasing
infection of the host cells, allowed us to infer that those previous
results were not under the influence of off-target effects, but rather
were real hits.
We further checked if the hits found in the U2OS screening
were also involved in the infection of HeLa cells, a cell line widely
used for T. cruzi invasion studies. Our results demonstrated that
most of the hits discovered in U2OS were also found to disturb T.
cruzi infection in HeLa cells, pointing towards the existence of
common pathways used by the parasite when infecting these
different cell lines. On the other hand, we discovered that two of
the hits, LOC389895 (Hypothetical LOC389895) and
MGC33951 (Chromosome 15 open reading frame 43), were
specific to U2OS cells, what suggests that the parasite may also
make use of cell specific factors during infection.
Analysis of the 13 genes whose knockdown affected the T. cruzi
infection process in U2OS cells revealed that several of the hits
were genes coding for cell membrane proteins, which may be
involved in signaling cascades triggered by T. cruzi or in the
attachment of these parasites to the host cells. The five hits that
localize at the cellular membrane are calcium binding protein 2
(CABP2), cadherin 11 type 2 OB-cadherin (osteoblast) (CDH11),
olfactory receptor family 2 subfamily T member 5 (LOC401993),
protocadherin alpha 13 (PCDHA13), and proline-rich membrane
anchor 1 (PRIMA1). Other hits have their location inferred by
similarity to their protein family members, such as calcium binding
protein P22 (CHP), which is located at the cell cytoplasm (UniProt
accession number Q99653), fucosyltransferase 8 (FUT8), which is
present at the Golgi membrane (UniProt accession number
Q9BYC5), and chemokine C-C motif ligand 4-like 1 (CCL4L1)
and collagen type VI alpha 6 (LOC131873), which are both
secreted proteins (UniProt accession numbers Q8NHW4 and
A6NMZ7, respectively). Functionally, four of the hits are related to
calcium-ion binding, which is consistent with previous evidence
that T. cruzi triggers Ca
2+ release on host cells to initiate the
invasion process [9,42–45]. The hits C20orf200, FLJ32783,
LOC389895, MGC33951 and NICE-3 did not provide any
information regarding subcellular location or molecular function
because they are hypothetical or uncharacterized proteins. Thus,
further experiments are necessary to validate these potential
targets.
Particularly interesting was the fact that, in our screening, we
identified several genes related to the TGF-beta-1 receptor,
including FUT8 and CDH11. TGF-beta receptors are associated
with T. cruzi infection in mammalian cells because inhibition of
TGF-beta signaling in vivo decreases infection and prevents heart
damage in mice [46]. In addition, secreted trypomastigote
molecules are able to stimulate TGF-beta receptors in epithelial
cells; treatment with TGF-beta greatly enhances T. cruzi invasion,
while cell lines that lack these receptors have been shown to be
resistant to T. cruzi infection [47]. There is evidence that the FUT8
protein, one of our hits, can increase TGFBR1 activation in
embryonic fibroblasts and that mouse Fut8-deficient cells exhibit
marked dysregulation of the TGF-b1 receptor and intracellular
signaling [48,49]. In agreement with those previous findings, we
show here that U2OS cells bearing low levels of FUT8 protein
exhibit a decreased infection ratio, potentially due to inefficient
TGF-beta pathway signaling.
CDH11, also known as cadherin 11, is another protein member
of the TGF-beta signaling pathway that we identified in our
screenings. Members of the TGF-beta superfamily indirectly
modulate cell adhesion by controlling cell surface levels of
cadherins, integral membrane proteins that mediate calcium-
dependent cell-cell adhesion [50,51]. Cell-cell adhesion molecules
expressed by host cells have also been shown to act as receptors for
the binding of infectious agents [52–54]. In Listeria monocytogenes, for
example, Internalin A protein is essential for efficient bacterial
penetration into human epithelial cells, and this property is
mediated by its binding to human E-cadherin in a Ca
2+-dependent
manner [53]. Another example is the neural cell adhesion
molecule [NCAM], considered one of the in vivo receptors for
the rabies virus in mice [54]. This same NCAM is an important
cell-cell adhesion protein found in cardiomyocytes and may also
act as a receptor for tissue targeting and cellular invasion by T.
cruzi in Chagas disease. This idea is supported by a previously
published study that showed that these parasites expressed
NCAM-like proteins and that cellular NCAM was reported to
be upregulated in Chagas disease myocarditis [55]. N-cadherins
are very abundant proteins in the mammalian heart as well, and
although no evidence has been found identifying cadherins as
receptors involved in T. cruzi entry into host cells, it is reasonable
to hypothesize that they might play a role during the T. cruzi
infection process, not only as potential receptors, but also as
signaling mediators.
Other hits found in this screening that were categorized as
secreted proteins, such as chemokine C-C motif ligand 4-like 1
(CCL4L1) and collagen type VI alpha 6 (LOC131873/
COL6A6), could have direct implications on the course of
infection. Whereas the former is a chemokine involved in
immunoregulatory and inflammatory processes [56], the latter is
an extracellular matrix component that helps cells remain
attached to the matrix to maintain tissue integrity [57]. Specific
interactions between T. cruzi molecules and components of the
extracellular matrix have already been described in previous
studies [58–60]. In addition, T. cruzi trypomastigotes present on
their surface collagen-binding proteins that can be involved in
cell-parasite interaction [60].
Previous work using RNAi has shown that genes like laminin c-
1 [17], thrombospondin-1 [18], and cytokeratin 18 [19] are
important for T. cruzi invasion of smooth muscle or HeLa cells.
The fact that we did not identify these genes in our screening may
be explained by differences in specific assay conditions used in the
various studies that can greatly influence the results of screening,
including cell type, parasite strain and/or infection time.
In summary, using genome-wide RNAi, we identified 14 host
cell genes that proved to be necessary for T. cruzi infection,
exposing as yet unrecognized factors in the host-pathogen
interplay. The analysis of these key players and the molecular
basis of their interactions will enable us to better understand the
pathogenesis of Chagas disease and potentially reveal new targets
for antiparasitic therapies. In addition, we have demonstrated that
the experimental approach employed in this study is a valid tool to
screen for human host factors that play a role in T. cruzi infection,
and it is applicable to the study of factors involved in the infection
of other pathogenic organisms as well.
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Figure S1 Schematic representation of the assay design.
U2OS cells were seeded over 7 glass slides containing 3,888 spots
each. The siRNA was reverse transfected into the cells, and
48 hours later the transfected cells were infected with T. cruzi
trypomastigotes. After 8 hours, the free parasites were washed out
and the slides were incubated for an additional 28 hours. Cells and
parasites were then fixed in 4% paraformaldehyde and stained
with DRAQ5 for imaging. All slides were imaged in two channels,
one for the spots stained with siGLO Red and another for cells
stained with DRAQ5.
(TIF)
Video S1 Video showing the software analysis in oper-
ation. This video shows a whole microarray slide being analyzed
by our customized software. First, a plug-in for fitting the gene
information over each spot is executed (pink squares), providing
spot localization on the microarray slides and showing all the
missing spots (green squares). When the arrow points to a
particular spot, the gene name and spot coordinates are shown,
providing specific information related to that gene. In the right
panel, the analysis plug-in is running, showing individual cell
detection and quantification in operation. At the end of the
process, a high-content description of each experiment is obtained,
including infection and normality measurements. The spots are
pseudocolored in red. For more information, see Materials and
Methods.
(MPG)
Table S1 Primers used for qRT-PCR.
(DOC)
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